Page 314 - Drug Class Review
P. 314
Page 187 of 205
Drug Effectiveness Review Project
placebo NR for subgroup 10.3% placebo 17% 8%
galantamine NR for subgroup 19.7% Post randomization exclusions: Yes Overall loss to follow-up: 135 (23%) Loss to follow-up differential high: No galantamine 26% 20%
NR ITT: Yes Yes Yes Yes Fair
Final Report Update 1 Authors: Erkinjuntti et al. Year: 2002 ADVERSE EVENTS: Overall adverse effects reported: Nausea for AD subgroup • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
